| Zeng, Xiaofeng |
NCT05899907: Efficacy and Safety of Telitacicept in Early SLE |
|
|
| Recruiting | 4 | 180 | RoW | Telitacicept, RC18, Standard of Care | Peking Union Medical College Hospital, RemeGen Co., Ltd. | Lupus Erythematosus, Systemic | 03/25 | 09/25 | | |
NCT04312815: A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX |
|
|
| Recruiting | 3 | 510 | RoW | SM03, Placebo, MTX | SinoMab Pty Ltd | Rheumatoid Arthritis(RA) | 12/21 | 07/22 | | |
NCT05324163: Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis |
|
|
| Completed | 3 | 180 | RoW | X0002 Spray, Test drug, Celecoxib capsules, Active comparator, placebo, Placebo Spray | Jiangsu XinChen-Techfields Pharma Co., LTD. | KNEE OSTEOARTHRITIS | 02/23 | 02/23 | | |
NCT06276998: A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis |
|
|
| Recruiting | 3 | 430 | RoW | LNK01001, Placebo | Lynk Pharmaceuticals Co., Ltd | Rheumatoid Arthritis | 08/25 | 11/26 | | |
NCT05881785: Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis |
|
|
| Completed | 3 | 465 | RoW | GR1501 low dose, GR1501 high dose, placebo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Axial Spondyloarthritis | 12/23 | 05/24 | | |
TARA, NCT06020144: A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs |
|
|
| Recruiting | 3 | 450 | RoW | TLL-018, TLL-018 tablets, Tofacitinib, Tofacitinib tablets | Hangzhou Highlightll Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 02/25 | 09/25 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
NCT05133297: The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis |
|
|
| Completed | 2a | 101 | RoW | TLL-018, Sequence 1, Sequence 2, Sequence 3, Tofacitinib, Sequence 4 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 12/22 | 05/23 | | |
NCT05967520: JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 2a | 48 | RoW | JMKX000189, Placebo | Jemincare | Lupus Erythematosus, Systemic | 05/25 | 12/25 | | |
NCT05162937: to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis |
|
|
| Completed | 2 | 160 | RoW | IL-17A antibody | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Axial Spondyloarthritis | 07/21 | 11/21 | | |
| Recruiting | 2 | 146 | RoW | Sirolimus, rapamycin, Placebo | Chinese SLE Treatment And Research Group, Beijing Municipal Science & Technology Commission, North China Pharmaceutical Group Corporation | Systemic Lupus Erythematosus | 10/24 | 05/25 | | |
NCT06085534: A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis |
|
|
| Completed | 2 | 177 | RoW | LNK01001, Placebo | Lynk Pharmaceuticals Co., Ltd | Ankylosing Spondylitis | 12/22 | 06/23 | | |
NCT06099535: A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis |
|
|
| Completed | 2 | 156 | RoW | LNK01001 Dose A, LNK01001 Dose B, placebo | Lynk Pharmaceuticals Co., Ltd | Rheumatoid Arthritis | 12/22 | 04/23 | | |
NCT05407246: Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis |
|
|
| Completed | 2 | 90 | RoW | Hemay005, placebo | Tianjin Hemay Pharmaceutical Co., Ltd | Active Ankylosing Spondylitis | 08/23 | 08/23 | | |
NCT05504083: Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients |
|
|
| Completed | 2 | 121 | RoW | D-0120, Benzbromarone | InventisBio Co., Ltd | Hyperuricemia | 05/24 | 05/24 | | |
NCT06222671: A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) |
|
|
| Not yet recruiting | 2 | 180 | RoW | 608, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Axial Spondyloarthritis | 11/25 | 11/25 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
NCT04971980: Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis |
|
|
| Recruiting | 1/2 | 9 | RoW | hUC-MSC infusion (BC-U001) | Beijing Baylx Biotech Co., Ltd. | Rheumatoid Arthritis | 12/22 | 01/23 | | |
NCT06015230: Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE |
|
|
| Active, not recruiting | 1/2 | 136 | RoW | low dose GR1603 in phase Ⅰb, high dose GR1603 in phaseⅠb, low dose GR1603 in phase Ⅱ, high dose GR1603 in phase Ⅱ, Placebo in phase Ⅱ | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Lupus Erythematosus, Systemic | 06/28 | 10/28 | | |
NCT06297408: Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1 | 24 | NA | Relma-cel, if necessary can add other anti-SLE treatment such as corticosteroids, immunosuppressants, biologics | Shanghai Ming Ju Biotechnology Co., Ltd. | Systemic Lupus Erythematosus | 05/25 | 05/26 | | |
| Zhou, Daobin |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT05441761: Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL |
|
|
| Recruiting | 1/2 | 60 | RoW | liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin | Peking Union Medical College Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | Treatment, Peripheral T-cell Lymphoma | 05/25 | 05/25 | | |
